SCYNEXIS Inc. Daily Stock Analysis

Daily Stock Analysis, SCYX, SCYNEXIS Inc, priceseries

SCYNEXIS Inc. Daily Stock Analysis
Stock Information
Open
3.87
Close
3.71
High
3.91
Low
3.66
Previous Close
3.87
Daily Price Gain
-0.16
YTD High
6.77
YTD High Date
Jan 3, 2022
YTD Low
3.66
YTD Low Date
Mar 7, 2022
YTD Price Change
-2.95
YTD Gain
-44.29%
52 Week High
10.25
52 Week High Date
Jun 1, 2021
52 Week Low
3.66
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-4.55
52 Week Gain
-55.08%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 6. 2017
31.50
Feb 22. 2017
33.56
11 Trading Days
6.53%
Link
LONG
Jun 20. 2017
17.00
Jun 30. 2017
17.95
8 Trading Days
5.62%
Link
LONG
Aug 25. 2017
18.50
Sep 15. 2017
20.42
14 Trading Days
10.39%
Link
LONG
Nov 30. 2017
19.90
Dec 20. 2017
22.34
14 Trading Days
12.25%
Link
LONG
May 11. 2018
12.70
Jun 4. 2018
16.40
15 Trading Days
29.17%
Link
LONG
Jan 3. 2019
5.47
Jan 23. 2019
7.34
13 Trading Days
34.28%
Link
LONG
Apr 2. 2019
15.50
Apr 15. 2019
16.87
9 Trading Days
8.85%
Link
LONG
Dec 23. 2019
7.93
Jan 22. 2020
10.21
19 Trading Days
28.68%
Link
LONG
Feb 13. 2020
9.40
Feb 25. 2020
9.96
7 Trading Days
5.96%
Link
LONG
Nov 5. 2020
4.73
Dec 3. 2020
6.35
19 Trading Days
34.35%
Link
LONG
Feb 1. 2021
7.58
Feb 11. 2021
8.71
8 Trading Days
14.97%
Link
LONG
May 14. 2021
7.11
Jun 2. 2021
8.51
12 Trading Days
19.73%
Link
Company Information
Stock Symbol
SCYX
Exchange
NasdaqGM
Company URL
http://www.scynexis.com
Company Phone
201-884-5485
CEO
Marco Taglietti
Headquarters
New Jersey
Business Address
101 HUDSON STREET, SUITE 3610, JERSEY CITY, NJ 07302-6548
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001178253
About

SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives which addresses the significant unmet therapeutic needs. It is currently developing a lead product candidate, SCY-078, a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Durham, NC.

Description

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading